

LA JOLLA PHARMACEUTICAL COMPANY
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Revenue				
Net product sales	\$ 3,470	\$ —	\$ 5,872	\$ —
Total revenue	3,470	—	5,872	—
Operating expenses				
Cost of product sales	256	—	443	—
Research and development	30,439	19,093	89,735	57,666
Selling, general and administrative	21,139	7,390	66,319	18,915
Total operating expenses	51,834	26,483	156,497	76,581
Loss from operations	(48,364)	(26,483)	(150,625)	(76,581)
Interest (expense) income, net	(2,381)	195	(3,426)	324
Net loss	\$ (50,745)	\$ (26,288)	\$ (154,051)	\$ (76,257)
Net loss per share, basic and diluted	\$ (1.93)	\$ (1.19)	\$ (6.15)	\$ (3.65)
Weighted-average common shares outstanding, basic and diluted	26,226	22,125	25,055	20,900